Similar articles

• Influence of thyroid status on plasma half-life of antipyrine in man.

  Eichelbaum M, Bodem G, Gugler R, Schneider-Deters D, Dengler HJ. Eichelbaum M, et al. N Engl J Med. 1974 May 9;290(19):1040-2. doi: 10.1056/NEJM197405092901902. N Engl J Med. 1974. PMID: 4821905 No abstract available.
• Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.

  Teunissen MW, van der Veen EA, Doodeman PJ, Breimer DD. Teunissen MW, et al. Eur J Clin Pharmacol. 1984;27(1):99-103. Eur J Clin Pharmacol. 1984. PMID: 6489432
• Unaltered metabolism of phenytoin in thyroid disorders.

  Mølholm Hansen J, Skovsted L, Kampmann JP, Lumholtz BI, Siersbaek-Nielsen K. Mølholm Hansen J, et al. Acta Pharmacol Toxicol (Copenh). 1978 May;42(5):343-6. doi: 10.1111/j.1600-0773.1978.tb02214.x. Acta Pharmacol Toxicol (Copenh). 1978. PMID: 581029
• Drug pharmacokinetics in thyroid dysfunction.

  Rodighiero V. Rodighiero V. Minerva Endocrinol. 1985 Apr-Jun;10(2):97-113. Minerva Endocrinol. 1985. PMID: 2415808 Review. No abstract available.
• [Thyroid gland and pregnancy--physiology and pathology].

  Łacka K, Łakoma H. Łacka K, et al. Wiad Lek. 2002;55(7-8):450-62. Wiad Lek. 2002. PMID: 12428574 Review. Polish.